News
Alumnus Spotlight on Meet Vora
GraphWear has raised $28 million in funding to date, enabling critical advancements in its technology and expanding its reach through clinical trials and strategic collaborations. As an MBC BioLabs alumnus, Meet’s story exemplifies the entrepreneurial spirit and dedication fostered by the MBC BioLabs community, reflecting how innovation can thrive from modest beginnings.
BridgeBio’s Attruby™ (acoramidis) approved by FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients
The U.S. Food and Drug Administration (FDA) approved Attruby™ (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.
OneSkin closes $20M series A investment round, fueling the future of skin longevity with advanced research
OneSkin is a best-in-class biotech skin health brand on a mission to revolutionize how we age. Created by four pioneering female scientists - OneSkin believes in research first, products second. That's why its founders spent five years analyzing over 900 peptides before discovering OS-01, the first ingredient scientifically proven to reverse skin's biological age.
Myka Labs partners with Mayo Clinic to develop next-gen AI for surgery
The Myka Labs-Mayo Clinic collaboration has a near-term focus on developing tools for gastroenterologists and surgeons performing procedures to diagnose and treat disease in the pancreas and other abdominal organs, with a longer-term view toward developing wide-ranging artificial intelligence-based innovations that positively impact patient care across a broad spectrum of medical conditions.
Dren Bio Announces Strategic Collaboration with Novartis
We are thrilled to share the news of a strategic collaboration between Dren Bio, one of our distinguished alumni, and Novartis to develop bispecific antibody therapies targeting cancer. This partnership, which builds on Dren Bio’s targeted myeloid engager and phagocytosis platform, includes an upfront payment of $150 million from Novartis, with $25 million as an equity investment.
MBC Alumni, Proteologix, Acquired by J&J for 850M
This acquisition highlights Proteologix's groundbreaking work in the treatment of atopic dermatitis.
We Are Proud to Announce our Partnership with HitGen to Accelerate Biotechnology Discovery!
LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, today announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).
Resident Company, Iaterion Inc., Received Funding To Accelerate Development of Women’s Health and Oncology Platform
Iaterion, Inc. received financing of undisclosed amount from Capital K, a venture capital fund in Silicon Valley, California
Integrated Biosciences Announces Nature Publication Identifying New Class of Antibiotics Discovered Via Company’s AI-Powered Platform
Publication validates the use of explainable deep learning in drug discovery and identifies a new class of antibiotics, one of the few in 60 years
Kate Hudson Joins Symbiome as Creative Advisor
Academy Award-nominated actress Kate Hudson, an avid Symbiome customer, has joined the MBC resident company as Creative Advisor.
MBC BioLabs Alum, Loyal, Makes Headlines with their Pioneering Longevity Drugs for Dogs
Aiming to bridge the longevity gap between breeds, Loyal, a pet longevity company, is on the verge of a veterinary breakthrough
Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
LabCentral, BioLabs, and MBC BioLabs announced an agreement to boost early-stage innovations through access to Evotec’s leading shared end-to-end R&D platform.
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis
Ionic Liquids - Changing the Game One Indication at a Time
This Startup Just Raised $26 Million To Develop Safer Gene Editing Tools
Amber Bio Raises 26M to Develop Safer Gene-Editing Tools
UCSF researchers’ startup aims to stop allergies — starting with babies’ guts
UCSF spinout targets allergic diseases by resetting babies' guts
Forbes 30 under 30 List
Felix Wong Cofounder, Integrated Biosciences Cambridge, Massachusetts Read original [...]
Venture Capitalist ROBUST Announces Investment in Symbiome
Venture Capitalist ROBUST Announces Investment in Sustainable Life Sciences Brand Symbiome
Industry Winner of the 2022 Grant Program
The winner of the industry category was Dr. Julia Durack from Symbiome in the USA!
Podcast: Building the Bay Area Life Sciences Startup Ecosystems
Lab to Startup Podcast with Regis Kelly and Doug Crawford
Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study
Siolta initiates dosing in newborn subjects in a groundbreaking trial of STMC-103H
Switch Bioworks Raises $4.3M to Feed a Growing World Sustainably
Next-generation biofertilizer startup sets out to tackle climate change with synthetic biology and microbes.
MBC BioLabs Announces New Partnership with Benchling
Benchling’s R&D Cloud makes it easier to capture and access the data you need, collaborate as a team, and accelerate decision making.
MBC BioLabs is Excited to Welcome Shimadzu as its Newest Partner
Shimadzu's Nexera Prep HPLC System is available at MBC BioLabs @ 930 Brittan.